Table 2.
Comparison of treatment patterns 6 months pre- and postswitch to once-monthly paliperidone palmitate (PP1M) among patients who initiated treatment with risperidone or paliperidone (RIS/PALI).
| Treatment pattern | 6 months pre-PP1M switch (n = 676) | 6 months post-PP1M switch (n = 676) |
|---|---|---|
| AP use | ||
| Any oral APs | 676 (100.0)* | 405 (59.9)* |
| Atypical oral APs | 676 (100.0)* | 395 (58.4)* |
| Any LAI APs | 162 (24.0)* | 676 (100.0)* |
| Atypical LAI APs | 124 (18.3)* | 676 (100.0)* |
| Antidepressants | 419 (62.0)* | 405 (59.9)* |
| Anxiolytics | 316 (46.8)* | 305 (45.1)* |
| Mood stabilizers | 326 (48.2)* | 299 (44.2)*† |
| PDC‡ | ||
| Any agent | 0.6 (0.3)§ | 0.8 (0.3)†§ |
| ≥80% | 221 (32.7)* | 430 (63.6)*† |
| RIS/PALI | 0.4 (0.3)§ | 0.2 (0.3)†§ |
| ≥80% | 111 (16.4)* | 45 (6.7)*† |
| PP1M | – | 0.6 (0.3)§ |
| ≥80% | – | 267 (39.5)* |
| MPR|| | ||
| Any agent | 0.7 (0.3)§ | 0.9 (0.2)†§ |
| ≥80% | 328 (48.5)* | 539 (79.7)*† |
| RIS/PALI | 0.5 (0.3)§ | 0.3 (0.4)†§ |
| ≥80% | 174 (25.7)* | 117 (17.3)*† |
| PP1M | – | 0.7 (0.4)§ |
| ≥80% | – | 335 (49.6)* |
AP = antipsychotic; LAI = long-acting injectable; MPR = medication possession ratio; PDC = proportion of days covered.
⁎
Value is presented as n (%).
†
P < 0.05.
‡
Defined as the sum of nonoverlapping days of supply divided by a fixed period (ie, 6 or 12 months) and the MPR. Adherence to therapy was defined as PDC ≥80%.
§
Value is presented as mean (SD).
||
Defined as the sum of the days of supply during exposure divided by the duration of exposure to therapy. Adherence to therapy was defined as MPR ≥80%.